Navigation Links
Novel Compound Shows Promise for Treatment of Alcoholism
Date:9/11/2008

discovery of new therapeutic compounds for treating alcoholism and related disorders."

The Preclinical Development Group that Dr. Bartlett leads at the UCSF-affiliated Gallo Center was established to develop new treatments and bridge the gap between research and clinical treatment. The purpose of the study was to find improved compounds for the treatment of alcoholism. "The study results demonstrate that this compound causes selective and long-lasting reductions of ethanol consumption and suggests the compound might be a promising candidate as a novel treatment for alcoholism. This study indicates that compounds with a higher affinity for delta opioid receptors and reduced affinity for mu opioid receptors might be better treatment candidates than Naltrexone, the current FDA approved treatment for alcoholism", said Dr. Bartlett.

"The study on SoRI-9409 and alcohol cessation has yielded vital data that will help fuel novel treatments for a devastating and very difficult-to-treat illness," said Dr. Bartlett. "To date, we have considered and evaluated other compounds, and theories, but the information yielded from this study, along with previous research on this particular compound, has proven to be the most promising to date. We are looking forward to collaborating with our partner, Southern Research, to enter the next phase of research." The research was also supported by the State of California for Medical Research on Alcohol and Substance Abuse and Department of Defense.

Southern Research operates a successful drug discovery research program resulting in six FDA approved drugs with six additional drug candidates in late-stage preclinical and early clinical development.

"Much of our success stems from having a highly successful medicinal chemistry group, and seeking out collaborators who are driven to help us develop new lead compounds and bring those drugs to market," said David Harris, director of Business Development for the Drug Disco
'/>"/>

SOURCE Southern Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
2. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
7. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
8. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 2Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 3Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 4Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 5American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 1American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 2American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 3American Health Assistance Foundation 26 Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Pr 52020 4Parents of Children With Autism Report High Stress Levels 52016 1Parents of Children With Autism Report High Stress Levels 52016 2Parents of Children With Autism Report High Stress Levels 52016 3New Five Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 52012 1New Five Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 52012 2New Five Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 52012 3New Five Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 52012 4
Other Medicine News:Health News:Julie Gallagher Joins Akerman Senterfitt's Healthcare Practice 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 3Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 4Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 5Health News:Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009 2Health News:DURECT to Participate in Cowen and Company Healthcare Conference 2Health News:More Vitamin C May Mean Less Chance of Gout 2Health News:Study: Doctor-patient conversations at end of life associated with lower medical expenses 2